A Phase 2 interventional study of VERVE-102 and Placebo in Atherosclerosis, Cardiovascular Disease and Hypercholesterolemia, sponsored by Verve Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Verve Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 3 that started in 2026, is one of 4 in phase 2, and was the 10th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Czechia and 4 more countries
Ages 45–80
Eli Lilly and Company · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Verve Therapeutics, Inc. · Sites in New Zealand, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 175 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 252 across the 9 interventional studies, 116 across the 1 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Verve Therapeutics, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Verve Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
1 of the studies in Atherosclerosis by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07783802Eli Lilly and CompanyA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single dose of VERVE-102 intravenously (IV)
Drug: VERVE-102
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
Participants will receive a single dose of placebo IV
Drug: Placebo
Administered IV
Also known as: LY4636581
Administered IV
Percent Change from Baseline in LDL-C
Time frame: Baseline, Day 90
Percent Change from Baseline in LDL-C
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline Total Cholesterol
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Apolipoprotein B
Time frame: Baseline to End of Study (up to Day 365)
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.
Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 23 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.